{
  "meta": {
    "timestamp": "2025-01-06T14:10:29.531934",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Apogee Therapeutics Inc.",
      "symbol": "APGE",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Clinical trial risks, including potential failures or delays",
            "Regulatory hurdles and unpredictability in obtaining approvals",
            "Dependence on external funding for operations and pipeline progress",
            "High competition in the biopharmaceutical industry",
            "Intellectual property challenges and potential infringement claims"
          ],
          "controversies": [
            "Insider transactions, such as Carl Dambkowski selling shares in January 2024"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Addressing high unmet needs in inflammatory and immune diseases"
          ],
          "governance_issues": [
            "Leadership changes, including the appointment of Mark C. McKenna as Chairman of the Board"
          ],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Apogee Therapeutics Inc | Reuters",
              "snippet": "Apogee Therapeutics Inc. ... Acelyrin's skin disease drug trial failure wipes off IPO gains. September 12, 2023. ... See here for a complete list of exchanges and delays.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125682+00:00",
              "published_date": null,
              "source_hash": "e58e4ad68781a6b7f74e816684f7dac8"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Highlights Progress and Best-in-Class Potential of ...",
              "snippet": "SAN FRANCISCO and WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125786+00:00",
              "published_date": null,
              "source_hash": "bc3f76cde36df95f07cdd362f0eda8b5"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics | Our Science",
              "snippet": "Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need ... Our ongoing study is testing APG777 dosed either every three or six months in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125801+00:00",
              "published_date": null,
              "source_hash": "cfe0dd2415228c6b9ebfa21ed086a92a"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics | Best-in-Class Therapies for Immunological and ...",
              "snippet": "Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058564+00:00",
              "published_date": null,
              "source_hash": "bce8a4d2385441b9b735a730a7883f5a"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Provides Pipeline Progress and Reports - GlobeNewswire",
              "snippet": "Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125823+00:00",
              "published_date": null,
              "source_hash": "d6cfcc0d2351009ab2d9d9a8ace085f4"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Announces First Participants Dosed in Phase 1 ...",
              "snippet": "SAN FRANCISCO and WALTHAM, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125832+00:00",
              "published_date": null,
              "source_hash": "7fa72069fbed3c6b0b512905eb218aa1"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (APGE) - Stock Analysis",
              "snippet": "Get a real-time Apogee Therapeutics, Inc. (APGE) stock price quote with breaking news, financials, statistics, charts and more. ... Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to poten...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125843+00:00",
              "published_date": null,
              "source_hash": "d9e721fe5a0f446e3671786d2c462250"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics | Meet the People that Power Progress",
              "snippet": "Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need ... Patients Apogee Commitment Science Simplified Clinical Trials & Disease Ed ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125852+00:00",
              "published_date": null,
              "source_hash": "c11012e804639279e6fbff50c78b6f99"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Company Profile - Dun & Bradstreet",
              "snippet": "/ Apogee Therapeutics, Inc. Apogee Therapeutics, Inc. Website. Get a D&B Hoovers Free Trial. Overview ... Get a D&B Hoovers Free Trial. Stay on top of your Business Credit File. Get full access to view your D&B business credit file now for just $39/month! View D&B Scores & Ratings. Discover.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125861+00:00",
              "published_date": null,
              "source_hash": "08f591427630969749cb14362cb9420b"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Advances Clinical Trials for APG333",
              "snippet": "The latest announcement is out from Apogee Therapeutics, Inc. ( ). Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG333, a promising monoclonal antibody ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:04.125870+00:00",
              "published_date": null,
              "source_hash": "8807dd65ea3f7eeb8e06a5432a001f24"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (APGE)",
              "snippet": "Looking at Apogee ... with clinical trial planning underway in asthma and COPD SAN FRANCISCO and WALTHAM, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:06.581382+00:00",
              "published_date": "2024-12-31T00:00:00+00:00",
              "source_hash": "29d8f5d0503eb568358e424bc3a2fb6f"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Advances Clinical Trials for APG333",
              "snippet": "Inc. ( (APGE)). Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG333, a promising monoclonal antibody designed to treat asthma, COPD, and broader ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:06.581468+00:00",
              "published_date": "2024-12-10T06:59:00+00:00",
              "source_hash": "0d3ad4ebe8a52b718f4d734d1535d721"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its ...",
              "snippet": "Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 Skip to main content You have permission to edit this article. Edit Close Newsletter Facebook ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:06.581482+00:00",
              "published_date": "2024-12-10T00:00:00+00:00",
              "source_hash": "3f43d4229172afecb635c4681d8f79ea"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics upsizes its IPO to $300m",
              "snippet": "In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics ... with a filing to start clinical trials due in the latter half ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:06.581492+00:00",
              "published_date": "2023-07-14T00:00:00+00:00",
              "source_hash": "40b2348db884df88a293691f2a881be3"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Announces Agenda for Virtual R&D Day",
              "snippet": "SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:10:06.581501+00:00",
              "published_date": "2024-11-29T10:01:00+00:00",
              "source_hash": "82ec745fbf6ad1a8175a1b1778f2b079"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Provides Pipeline Progress and Reports - GlobeNewswire",
              "snippet": "Apogee Therapeutics 2024 Virtual R&D Day to be held on December 2, 2024 at 10am ET: The company plans to highlight its progress across its pipeline and showcase its path to reshaping the standard ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043681+00:00",
              "published_date": null,
              "source_hash": "1819ea736a1b98193f2b40195436f9bf"
            },
            {
              "url": "",
              "title": "Release Details - Apogee Therapeutics, Inc.",
              "snippet": "In addition, Apogee reported second quarter 2023 financial results and provided guidance on its projected operating runway. \"We have achieved remarkable growth and progress across all aspects of Apogee's business in 2023 to date, marked by the important milestones of transitioning to both a publicly traded and clinical-stage company ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043783+00:00",
              "published_date": null,
              "source_hash": "2d6c74d4de9d4ba543fa07f8e06d0e22"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering ...",
              "snippet": "SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the closing of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043798+00:00",
              "published_date": null,
              "source_hash": "6f411632ac9637ec28ed417b2f2507bc"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Highlights Pipeline Progress and - GlobeNewswire",
              "snippet": "Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043808+00:00",
              "published_date": null,
              "source_hash": "57f2df0771f060ce37c9419f738d15cf"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (APGE) - Stock Analysis",
              "snippet": "Get a real-time Apogee Therapeutics, Inc. (APGE) stock price quote with breaking news, financials, statistics, charts and more. ... Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results. Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043818+00:00",
              "published_date": null,
              "source_hash": "dc8a3fccad3572ccfb18074cc0e04ca3"
            },
            {
              "url": "",
              "title": "Investor FAQs | Apogee Therapeutics, Inc.",
              "snippet": "Financial Information. SEC Filings. Annual Reports. Quarterly Results. IR Resources. Investor FAQs. Email Alerts. Contact IR. Investor FAQs. Show All. Press space to expand and collapse this section. Where is Apogee Therapeutics' corporate headquarters? Apogee is headquartered at 221 Crescent St., Building 17, Suite 102b, Waltham, MA 02453 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043828+00:00",
              "published_date": null,
              "source_hash": "b958f70c5f0e4929bd757be20fb0c1fa"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million ...",
              "snippet": "Apogee Therapeutics, LLC. SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043837+00:00",
              "published_date": null,
              "source_hash": "3a51374b697eee2bb2f0454703259de9"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering",
              "snippet": "Apogee Therapeutics, LLC. SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058554+00:00",
              "published_date": null,
              "source_hash": "b3436af68a9328210b64a55946ceb05d"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Provides Pipeline Progress and Reports Second ...",
              "snippet": "Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043854+00:00",
              "published_date": null,
              "source_hash": "d47a82d043382b82c9efbd15050e6ca2"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public ...",
              "snippet": "SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:10.043863+00:00",
              "published_date": null,
              "source_hash": "0e687b53e3aa1742cb83ee0f0a5c344f"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 Shares of Stock",
              "snippet": "XTX Topco Ltd bought a new position in Apogee Therapeutics in the second quarter worth about $706,000. Victory Capital Management Inc. boosted its stake in Apogee Therapeutics by 56.8% in the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:12.519084+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "8d33f18681a586e857d372d034e97de3"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics price target raised to $110 from $95 at Guggenheim",
              "snippet": "Guggenheim analyst Seamus Fernandez raised the firm's price target on Apogee Therapeutics (APGE ... market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:12.519164+00:00",
              "published_date": "2024-12-12T06:45:00+00:00",
              "source_hash": "368a242f85ef866eee5b7e58af6fc951"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Advances Clinical Trials for APG333",
              "snippet": "Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks The latest announcement is out from Apogee Therapeutics, Inc. ( (APGE)). Apogee Therapeutics has begun dosing ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:16.444789+00:00",
              "published_date": "2024-12-10T12:59:00+00:00",
              "source_hash": "9a22c3b881d514b3b0a0b8e6e41c72c8"
            },
            {
              "url": "",
              "title": "This Apogee Therapeutics Insider Increased Their Holding In The Last Year",
              "snippet": "Looking at Apogee Therapeutics, Inc.'s (NASDAQ:APGE ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. funding disruptions or financial instability",
              "retrieved_at": "2025-01-06T21:10:12.519186+00:00",
              "published_date": "2024-12-25T11:34:00+00:00",
              "source_hash": "95d95c25b1f1351d1c63f1784333d2b7"
            },
            {
              "url": "",
              "title": "Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)",
              "snippet": "There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apogee Therapeutics, Inc. (APGE - Research Report) and TransMedics Group (TMDX - Research ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:16.444799+00:00",
              "published_date": "2024-12-03T06:01:00+00:00",
              "source_hash": "4786ca0f9add775ec62d7ae75e44de42"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public ...",
              "snippet": "About Apogee Therapeutics. Apogee Therapeutics, Inc. is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (\"AD\"), chronic obstructive ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058413+00:00",
              "published_date": null,
              "source_hash": "2f5ce68bca23640d0103c956ce0b800d"
            },
            {
              "url": "",
              "title": "Release Details - Apogee Therapeutics, Inc.",
              "snippet": "Appointed Mark C. McKenna as Chairman of the Board: In August, Apogee expanded its board with the appointment of Mark C. McKenna, former Chairman, President and CEO of Prometheus Biosciences, Inc. which was acquired by Merck & Co., Inc. in June 2023 for approximately $10.8 billion, representing the largest pre-Phase 3 biopharma acquisition to ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058518+00:00",
              "published_date": null,
              "source_hash": "b6b679028a506f7746b6d42c56808b21"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. Announces Closing of Upsized - GlobeNewswire",
              "snippet": "Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058534+00:00",
              "published_date": null,
              "source_hash": "252243eefdce0c2534f037870ec4fff0"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Provides Pipeline Progress and Reports - GlobeNewswire",
              "snippet": "Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058544+00:00",
              "published_date": null,
              "source_hash": "890ff4efbff4b8f95f483acc90410734"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial ...",
              "snippet": "Apogee Therapeutics, LLC. Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058574+00:00",
              "published_date": null,
              "source_hash": "dc854dfe7f8a7a979fbb5b09f9b4b4ee"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Inc | Reuters",
              "snippet": "The latest international Apogee Therapeutics Inc news and views from Reuters - one of the world's largest news agencies",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058583+00:00",
              "published_date": null,
              "source_hash": "0f15a7da486ec628246da5fb26ecaf78"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics Announces Upsized $345.1 Million IPO - Cooley",
              "snippet": "San Diego - July 18, 2023 - Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company. Partners Div Gupta, Charlie Kim and Kristin VanderPas led the Cooley team advising the underwriters. Apogee sold 20,297,500 shares of its common stock at a public offering price of $17 per share, less underwriting discounts and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058592+00:00",
              "published_date": null,
              "source_hash": "d942ce2b7c5cd2558ed2e9c4e7967045"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln",
              "snippet": "Apogee Therapeutics Inc. APGE has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments for chronic obstructive pulmonary disease (COPD ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:14.058603+00:00",
              "published_date": null,
              "source_hash": "02f1fc3eaaa5164e1d1216ea1a7b6c95"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 Shares of Stock",
              "snippet": "Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $46.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:16.444735+00:00",
              "published_date": "2025-01-04T08:58:00+00:00",
              "source_hash": "61ccbf29d0e5b932e4600985e74dd0fb"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Geode Capital Management LLC",
              "snippet": "Geode Capital Management LLC lifted its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 11.2% during the third quarter, Holdings Channel.com reports. The fund owned 823,839 shares of the company's stock after purchasing an additional 82,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:16.444777+00:00",
              "published_date": "2024-12-24T07:58:00+00:00",
              "source_hash": "8cf9868e8d6eec610585aaf07ea89ae9"
            },
            {
              "url": "",
              "title": "Apogee Therapeutics price target raised to $90 from $87 at Wedbush",
              "snippet": "Wedbush raised the firm's price target on Apogee Therapeutics (APGE) to $90 from $87 and keeps an Outperform rating on the shares. The firm notes that ahead of its R&D Day, the company announced ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Apogee Therapeutics Inc. Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "retrieved_at": "2025-01-06T21:10:16.444807+00:00",
              "published_date": "2024-12-02T13:25:00+00:00",
              "source_hash": "0d163971dcc0b3492723301096117de2"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Apogee Therapeutics Inc. clinical trial failures or delays",
              "rationale": "Investigate potential risks associated with clinical trial outcomes and regulatory hurdles",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Apogee Therapeutics Inc. funding disruptions or financial instability",
              "rationale": "Assess the company's dependence on external funding and potential impacts on operations",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Apogee Therapeutics Inc. intellectual property disputes or patent challenges",
              "rationale": "Examine potential controversies related to intellectual property protection and infringement claims",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:10:29.531941",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}